2025-07-08 - Analysis Report
## RXRX (Recursion Pharmaceuticals Inc) Stock Analysis

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

Here's a comparison of RXRX's performance against the S&P 500 (VOO):

*   **RXRX Cumulative Return:** -51.24%
*   **VOO Cumulative Return:** 35.24%
*   **Absolute Divergence:** -86.48%
*   **Divergence Range:**
    *   Max: 35.8
    *   Min: -87.9
    *   Current: -86.2
    *   Relative Divergence: 1.4

**Analysis:** RXRX has significantly underperformed the S&P 500. The cumulative return difference is substantial. The Relative Divergence of 1.4 indicates that the current divergence is near the lowest end of its historical range, meaning RXRX is performing near its worst compared to VOO.

**Alpha, Beta Analysis:**

| Year        | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| ----------- | ------ | ------ | ------- | ------ | ------ |
| 2021-2023   | 5.0%   | 73.6%  | -1.0%   | -0.1   | 3.7    |
| 2022-2024   | 0.0%   | 73.6%  | -25.0%  | 0.1    | 2.5    |
| 2023-2025   | 0.0%   | 73.6%  | -48.0%  | 0.1    | 2.0    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) has decreased significantly over the periods.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant risk and potential for large losses.
*   **Alpha:** The negative Alpha indicates that the stock has underperformed its benchmark (risk-adjusted return). The decreasing Alpha values show worsening relative performance.
*   **Beta:** Beta values close to 0 suggest low correlation with the market. This could mean the stock's returns are less influenced by overall market movements.
*   **Cap(B):** The market capitalization has decreased over the periods, which might reflect declining investor confidence or company performance.

### 2. Recent Stock Price Movements

*   **Current Price:** 5.27
*   **Last Market Data:** {'price': 4.89, 'previousClose': 5.27, 'change': -7.24}
*   **5-Day Moving Average:** 5.14
*   **20-Day Moving Average:** 5.13
*   **60-Day Moving Average:** 4.94

**Analysis:** The current price of 4.89 indicates a significant drop (7.24% change). This recent decline suggests negative momentum. The 5-day and 20-day moving averages are relatively close, while the 60-day moving average is lower, indicating a possible short-term stabilization after a longer-term uptrend.

### 3. Risk and Return Indicators

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 52.14
*   **PPO:** 0.23
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (6 shares - Caution - MRI:0.33) (Cash Ratio: 0% on 2025-07-03)
*   **Recent (20-Day) Relative Divergence Change:** -2.2 (Negative)
*   **Expected Return (%):** -1845.0

**Analysis:**

*   **MRI:** The low MRI suggests relatively low market risk.
*   **RSI:** An RSI of 52.14 indicates a neutral market position, neither overbought nor oversold.
*   **PPO:** A PPO of 0.23 indicates that the short-term moving average is slightly above the long-term moving average, suggesting a weak uptrend.
*   **Hybrid Signal:** The signal suggests buying 80% with caution due to the MRI.
*   **Relative Divergence Change:** The recent negative change in relative divergence (-2.2) confirms the short-term downward trend compared to the S&P 500.
*   **Expected Return:** The extremely negative expected return (-1845%) indicates that, based on current analysis, long-term investment in RXRX is projected to significantly underperform the S&P 500. The recent drop in price {'price': 4.8883, 'previousClose': 5.27, 'change': -7.24} highlights significant negative volatility and potential investor concern.

### 4. Recent News & Significant Events

*   **[2025-07-05]:** Recent major business developments, regulatory changes, or market events.
*   **[2025-07-07]:** Analyst discussions on recent performance in the context of industry trends and global economic factors.
*   **[2025-07-08]:** Notable stock volatility due to recent news, earnings reports, or executive actions.
*   **[2025-07-04]:** Market experts highlighting risks and opportunities.

**Analysis:** Recent news indicates potential catalysts driving stock volatility and investor sentiment, highlighting the need for careful monitoring of company announcements and market reactions.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출       |
| ----------- | ----- | ---------- |
| 2025-05-05  | -0.50  | 0.01 B$    |
| 2024-11-06  | -0.34  | 0.03 B$    |
| 2024-08-08  | -0.40  | 0.01 B$    |
| 2024-05-09  | -0.39  | 0.01 B$    |
| 2025-05-05  | -0.39  | 0.01 B$    |

**Analysis:** Earnings per share (EPS) is consistently negative, indicating losses. Revenue fluctuates, but remains relatively low. The consistent losses suggest that the company is still in a growth phase and is not yet profitable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |
| 2024-03-31 | $0.01B    | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE        |
| ---------- | --------- | ---------- |
| 2025-03-31 | $0.93B    | -21.68%    |
| 2024-12-31 | $1.03B    | -17.29%    |
| 2024-09-30 | $0.52B    | -18.27%    |
| 2024-06-30 | $0.58B    | -16.69%    |
| 2024-03-31 | $0.40B    | -22.78%    |

**Analysis:**

*   **Revenue:** Revenue is inconsistent and relatively low.
*   **Profit Margin:** Profit margins are volatile and frequently negative, highlighting profitability challenges.
*   **Equity:** Equity fluctuates, but has generally increased over the past year.
*   **ROE:** Return on Equity (ROE) is consistently negative, indicating that the company is not generating profits from shareholder equity.

### 7. Overall Analysis

RXRX has significantly underperformed the S&P 500, with a large negative cumulative return difference. The company is currently experiencing negative momentum, as highlighted by the recent price drop and negative changes in relative divergence. Financial metrics reveal inconsistent revenue, negative profit margins, and negative ROE, indicating that the company is not yet profitable. Recent news suggests potential catalysts for volatility, while analyst discussions highlight risks and opportunities. The extremely negative expected return suggests a high-risk investment with substantial potential for underperformance compared to the broader market. The hybrid signal cautiously recommends a buy, but the overall analysis suggests caution and careful monitoring of company developments.
